Literature DB >> 21698412

Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.

Paul G Hammerness1, Craig B H Surman, Ashley Chilton.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder afflicting adults worldwide. This article is an update on the evidence supporting medications for adult ADHD, with particular emphasis on cardiovascular implications. Relevant clinical literature was sought using PubMed searches, with an emphasis on new reports from April 2009 to April 2011. This review describes the efficacy and general tolerability of stimulant and nonstimulant medications for adults with ADHD as seen in contemporary clinical trials. Cardiovascular response to medications for ADHD is primarily seen in heart rate and blood pressure elevations, while less is known about the etiology of rare cardiovascular events or long-term sequelae. Further research is indicated to delineate clinical and functional outcomes for adults with ADHD, as well as long-term safety of medication treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21698412     DOI: 10.1007/s11920-011-0213-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  44 in total

1.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

2.  Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members.

Authors:  Ronald C Kessler; Lenard A Adler; Michael J Gruber; Chaitanya A Sarawate; Thomas Spencer; David L Van Brunt
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

3.  Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

Authors:  Lenard A Adler; Richard H Weisler; David W Goodman; Mohamed Hamdani; Gwendolyn E Niebler
Journal:  J Clin Psychiatry       Date:  2009-12       Impact factor: 4.384

4.  Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.

Authors:  Tobias Gerhard; Almut G Winterstein; Mark Olfson; Cecilia Huang; Arwa Saidi; Stephen Crystal
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

5.  Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Authors:  Timothy E Wilens; Paul G Hammerness; Joseph Biederman; Anne Kwon; Thomas J Spencer; Sarah Clark; Megan Scott; Amy Podolski; Jeffrey W Ditterline; Matthew C Morris; Hadley Moore
Journal:  J Clin Psychiatry       Date:  2005-02       Impact factor: 4.384

6.  Atomoxetine treatment for ADHD: younger adults compared with older adults.

Authors:  Todd Durell; Lenard Adler; Timothy Wilens; Martin Paczkowski; Kory Schuh
Journal:  J Atten Disord       Date:  2010-01       Impact factor: 3.256

7.  Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.

Authors:  Victoria L Vetter; Josephine Elia; Christopher Erickson; Stuart Berger; Nathan Blum; Karen Uzark; Catherine L Webb
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

8.  Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

Authors:  Lenard A Adler; Thomas J Spencer; David W Williams; Rodney J Moore; David Michelson
Journal:  J Atten Disord       Date:  2008-04-30       Impact factor: 3.256

Review 9.  Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults.

Authors:  Christopher Gibbins; Margaret Weiss
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

10.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382

View more
  9 in total

1.  ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Authors:  Laurel A Habel; William O Cooper; Colin M Sox; K Arnold Chan; Bruce H Fireman; Patrick G Arbogast; T Craig Cheetham; Virginia P Quinn; Sascha Dublin; Denise M Boudreau; Susan E Andrade; Pamala A Pawloski; Marsha A Raebel; David H Smith; Ninah Achacoso; Connie Uratsu; Alan S Go; Steve Sidney; Mai N Nguyen-Huynh; Wayne A Ray; Joe V Selby
Journal:  JAMA       Date:  2011-12-12       Impact factor: 56.272

2.  Stimulant medication and postural orthostatic tachycardia syndrome: a tale of two cases.

Authors:  William P Cheshire
Journal:  Clin Auton Res       Date:  2016-03-11       Impact factor: 4.435

Review 3.  Improving postapproval drug safety surveillance: getting better information sooner.

Authors:  Sean Hennessy; Brian L Strom
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-09-25       Impact factor: 13.820

4.  A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.

Authors:  Earle E Bain; Weining Robieson; Yili Pritchett; Tushar Garimella; Walid Abi-Saab; George Apostol; James J McGough; Mario D Saltarelli
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

Review 5.  Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis.

Authors:  Hui Liu; Wenjing Feng; Dongfeng Zhang
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-08-24       Impact factor: 4.785

Review 6.  Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.

Authors:  Eric Mick; David D McManus; Robert J Goldberg
Journal:  Eur Neuropsychopharmacol       Date:  2012-07-15       Impact factor: 4.600

Review 7.  Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.

Authors:  Leonie Hennissen; Mireille J Bakker; Tobias Banaschewski; Sara Carucci; David Coghill; Marina Danckaerts; Ralf W Dittmann; Chris Hollis; Hanna Kovshoff; Suzanne McCarthy; Peter Nagy; Edmund Sonuga-Barke; Ian C K Wong; Alessandro Zuddas; Eric Rosenthal; Jan K Buitelaar
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

8.  High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report.

Authors:  Michael Liebrenz; Danielle Hof; Anna Buadze; Rudolf Stohler; Dominique Eich
Journal:  J Med Case Rep       Date:  2012-05-14

9.  Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults.

Authors:  Hedi Schelleman; Warren B Bilker; Stephen E Kimmel; Gregory W Daniel; Craig Newcomb; James P Guevara; Mark J Cziraky; Brian L Strom; Sean Hennessy
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.